article thumbnail

Mastering Responses to FDA 510(k) AI Letters: A Strategic Approach

The FDA Law Blog

FDA communicates via a Substantive Interaction to inform the submitter either that FDA will proceed with Interactive Review or that the 510(k) will be placed on hold until FDA receives a complete response to an Additional Information request. By Day 15 FDA conducts Acceptance Review. By Day 60 FDA conducts Substantive Review.

FDA 75
article thumbnail

Bridging the healthcare digital divide: a gradual approach to adopting ePI

European Pharmaceutical Review

7 Access to digital communications also remains a challenge in some Member States especially for those groups at risk of poverty and social exclusion (7.6 Article 63 EMA (29 January 2020). Even in countries with high smartphone usage such as Denmark, up to 25 percent of the population do not possess a smartphone.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Point of Care Testing: Increasing Your Pharmacy Profit

DiversifyRx

He created DB Diagnostics in 2020. All our cleared products have a package insert listed under the product, and all the information you need for the form is found there. In addition to selling tests, Kavel has solutions for online appointments, websites, and test results communication to patients or government entities.

article thumbnail

What can pharma marketing learn from other regulated industries?

pharmaphorum

“A lot of printed materials have been migrated to digital so that patients can opt-in to receive digital communications or HCPs can receive digital product or disease state information in the form of rep-triggered emails and microsites. Joanna Carlish. The idea is about really tapping into where the customer is in their journey.

article thumbnail

Innovation across the healthcare system is needed to realise the value of medicines

pharmaphorum

The European Commission’s Pharmaceutical Strategy for Europe , adopted in November 2020, outlines a series of concrete actions to ensure accessibility, availability, and affordability of medicines. Data will always be central to everything we do, as it has the power to communicate the potential of a new treatment to change a person’s life.

article thumbnail

Assumptions to evidence: How NINR project is solidifying UK’s remote trial know how

pharmaphorum

As the COVID-19 pandemic ricocheted around the world at the start of 2020, researchers were faced with a stark choice – go remote or go home. The ability to communicate with participants via video call may make the trial more inclusive geographically, but can also exclude people from a technology standpoint, for instance.

article thumbnail

Message from the Chair an Exciting Year

ISPE

Reintroducing the liaison role of International Board members with individual Chapters and Affiliates has given us direct lines of communication to the mutual benefit of the International Board and the local groups. What else did I do as Chair this year, in addition to running the Board and its meetings plus sitting on numerous committees?